Background and Objectives Spinal muscular atrophy (SMA) was added to the
Recommended Uniform Screening Panel in July 2018 largely on the basis of the availability …

The purpose of this study is to provide the results of the newborn screening (NBS) program
for Spinal Muscular Atrophy (SMA) in the state of Georgia to determine disease incidence …

Background: Spinal muscular atrophy (SMA) is characterized by the progressive loss of
motor neurons causing muscle atrophy and weakness. Nusinersen, the first effective SMA …

Prior to statewide newborn screening (NBS) for spinal muscular atrophy (SMA) in North
Carolina, USA, we offered voluntary screening through the Early Check (EC) research study …

Importance There is increasing evidence that early diagnosis and treatment are key for
outcomes in infants with spinal muscular atrophy (SMA), and newborn screening programs …

Purpose Spinal muscular atrophy (SMA) was added to the Recommended Uniform
Screening Panel (RUSP) in July 2018, following FDA approval of the first effective SMA …

Massachusetts began newborn screening (NBS) for Spinal Muscular Atrophy (SMA)
following the availability of new treatment options. The New England Newborn Screening …

Background In light of a new therapeutic era for spinal muscular atrophy (SMA), newborn
screening has been proposed as a gateway to facilitate expedient diagnosis and access to …

Spinal muscular atrophy (SMA) is a progressive neuromuscular disease caused by biallelic
pathogenic/likely pathogenic variants of the survival motor neuron 1 (SMN1) gene. Early …

Objective Infantile‐onset spinal muscular atrophy (SMA) is the most common genetic cause
of infant mortality, typically resulting in death preceding age 2. Clinical trials in this …